For Healthcare Professionals

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease


About the study

This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be efficacious over longer periods of time.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria

  1. Signed informed consent must be obtained prior to participation in the study.
  2. Clinically diagnosed Stage 1 or 2 Huntington's disease with a diagnostic confidence level (DCL) = 4 and a United Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) >8 at screening.
  3. Genetically confirmed Huntington's disease, with presence of ≥40 cytosine-adenineguanine (CAG) repeats in the huntingtin gene.
  4. Male and female participants between 25 to 75 years of age, inclusive, on the day of Informed Consent signature.


Exclusion Criteria

  1. Prior participation in clinical trial investigating a huntingtin-lowering therapy (unless participant received only placebo).
  2. Participants taking medications prohibited by the protocol.
  3. Any medical history, lumbar surgery or condition that would interfere with the ability to complete the protocol specified assessments,
  4. Participant has other severe, acute or chronic medical conditions including unstable psychiatric conditions, or laboratory abnormalities that in the opinion of the Investigator may increase the risk associated with study participation, or that may interfere with the interpretation of the study results.
  5. Any surgical or medical condition which might put the participant at risk in case of participation in the study. The Investigator should make this determination in consideration of the participant's medical history and/or clinical or laboratory evidence at the Screening visit:

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Early Manifest Huntington Disease

Age (in years)

25 - 75


Phase 2

Participants needed


Est. Completion Date

Oct 24, 2023

Treatment type



Novartis identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.